Elliott Investment Management L.P. Reduces $21M in CorMedix Inc. ($CRMD)
Key Points
- Elliott Investment Management L.P. changed its CorMedix Inc. ($CRMD) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $CRMD is Buy and an average price target of $15.20.
- $CRMD last traded around $8.74.
Elliott Investment Management L.P. reduced its position in CorMedix Inc. ($CRMD), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of CorMedix Inc. after selling 2,444,561 shares during the quarter.
CorMedix Inc. ($CRMD) Stock
CorMedix Inc. Earnings
Analysts Set New Price Targets
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.